Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
June 11, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
AB Science annonce aujourd'hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été présentés à la réunion annuelle 2021 de l'ASCO
June 10, 2021 12:54 ET
|
AB Science
COMMUNIQUE DE PRESSE PRESENTATION DES RESULTATS DE L’ETUDE AB12005 DU MASITINIB DANS LE CANCER DU PANCREAS A LA REUNION ANNUELLE DE L’ASCO ET PUBLICATION DU RESUME COMPLET DE L’ETUDE DANS LE...
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
June 10, 2021 12:54 ET
|
AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB12005 IN PANCREATIC CANCER PRESENTED AT THE ASCO ANNUAL MEETING WITH THE FULL ABSTRACT PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Paris, 10...
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Peptide Therapeutics Market to Outstrip $50,003.15 Million by 2027 Growing Sturdy at 9.2% CAGR - COVID-19 Impact and Global Analysis by TheInsightPartners.com
June 09, 2021 11:13 ET
|
The Insight Partners
Pune, India., June 09, 2021 (GLOBE NEWSWIRE) -- Peptide Therapeutics Market: Key InsightsAccording to our new research study on “Peptide Therapeutics Market to 2027 – Global Analysis and Forecast –...
Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool
June 08, 2021 10:30 ET
|
Precipio, Inc.
Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company...
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
June 08, 2021 07:54 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by PDS Biotechnology Corporation (Nasdaq: PDSB), we've been informed by the company,...
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
June 08, 2021 06:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
AB Science fournit le résumé de la conférence virtuelle qui s’est tenue le 3 juin 2021 suite à l’interruption volontaire des études cliniques du masitinib
June 08, 2021 02:30 ET
|
AB Science
COMMUNIQUE DE PRESSE RESUME DE LA CONFERENCE VIRTUELLE DU 3 JUIN 2021 SUITE A L’INTERRUPTION VOLONTAIRE DES ETUDES CLINIQUES DU MASITINIB REPRISE DE LA COTATION MERCREDI 9 JUIN 2021 Paris, 8 juin...